Galera Shares Halted After FDA Says Avasopasem Needs Additional Phase 3 Trial
Adriano Marchese
Shares in Galera Therapeutics were halted from premarket trading on Tuesday after the Food and Drug Administration said the company needs an additional Phase 3 trial for its treatment radiotherapy-induced severe oral mucositis.
The stock closed Monday at 21 cents on the Nasdaq exchange, down about 86% for the year to date.
The clinical-stage biopharmaceutical company said it received the official FDA meeting minutes in which the agency reiterated the need for another trial of avasopasem to support the resubmission of Galera's new drug application.
Galera also decided to halt a Phase 2b trial of rucosopasem manganese, which aimed to treat locally advanced pancreatic cancer, as well as a Phase 1/2 trial of the same drug to treat nonsmall cell lung cancer.
Galera said this decision will allow it to better conserve cash while it continues to assess potential strategic alternatives.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
October 31, 2023 07:54 ET (11:54 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
10 Top-Performing Dividend Stocks of the Month
-
Marathon Petroleum Earnings: No Change to Competitive Position, but Shares Look Expensive
-
Charlie Munger and How Not to Invest
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
After Earnings, Is AT&T Stock a Buy, a Sell, or Fairly Valued?
-
Mastercard Earnings: A Stable Environment Highlights the Firm’s Strengths
-
Pfizer Earnings: Solid Results Supported by Steady Tracking Toward $4 Billion In Cost Cuts
-
Starbucks Earnings: Not a Lot to Like About Results as Global Traffic Sputters